(2) DJ EQS-News: BOCI initiated coverage on iClick (NASDAQ: ICLK) at Overweight with a target price of USUSD21.3 EQS-News / 24/02/2021 / 09:33 UTC+8 BOCI initiated coverage on iClick (NASDAQ: ICLK) at Overweight with a target price of USUSD21.3 BOCI initiated coverage on iClick Interactive Asia Group Limited (NASDAQ: ICLK) at Overweight with a target price of USUSD21.3 on 23 February 2021, representing an upside of 57% from 22 February 2021 closing price of USUSD13.59. BOCI believes that iClick is a leading independent player in programmatic digital marketing in China, which operates the biggest independent marketing services platform and one of the fastest growing WeChat based SaaS enterprise platforms. The marketing services are backed by machine and AI-driven technology with extensive consumer data, analytics, and access to publishing channels, representing high barriers to entry. Currently, 4,000 KA clients with a low attrition rate of 5% is a proven stable revenue stre
TodayIR: Union Medical Healthcare proposes changing name to EC Healthcare to reflect business development
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update
February 12, 2021 GMT
LYON, France (BUSINESS WIRE) Feb 12, 2021
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the twelve months ended December 31, 2020 and provided a corporate update.
ADVERTISEMENT
“Despite the challenges posed by the COVID-19 pandemic, Poxel ended 2020 on a strong note, having accomplished several important corporate and clinical milestones and positioning the Company for an exciting 2021. We continued working closely with our partner Sumitomo Dainippon Pharma to further advance the review of the Japanese New Drug Application for Imeglimin follo
(1) DJ EQS-News: Merrill Lynch initiated coverage on China MeiDong Auto Holdings Limited (1268.HK) at Buy; TP of HKUSD40.50 EQS-News / 05/02/2021 / 15:05 UTC+8 Merrill Lynch initiated coverage on China MeiDong Auto Holdings Limited (1268.HK) at Buy; TP of HKUSD40.50 Merrill Lynch initiated coverage on China MeiDong Auto Holdings Limited (1268.HK) at Buy with a target price of HKUSD40.50, representing an upside of 56.0% from the closing price of HKUSD25.90 on 29th January. Merrill Lynch appreciates Meidong s differentiated strategy, which focuses on luxury brand car dealerships in fast-growing yet under-penetrated tier 3-5 cities, making it a key beneficiary from consumption upgrade as regional income rises. Merrill Lynch also likes Meidong s laser focus on high operating efficiency and inventory turnover, which sees the company generates significantly higher returns and faster growth than peers. Supported by its strong operating cash flow and net cash position, Merrill Lync
(2) DJ EQS-News: Jefferies Issued Updated Report on iClick (NASDAQ: ICLK) Maintained Buy and Raised Target Price from USUSD12.0 to USUSD17.4 EQS-News / 28/01/2021 / 20:32 UTC+8 Jefferies Issued Updated Report on iClick (NASDAQ: ICLK) Maintained Buy and Raised Target Price from USUSD12.0 to USUSD17.4 Jefferies issued an updated report on iClick Interactive Asia Group Limited (NASDAQ: ICLK) on 28 January 2021, maintaining its Buy rating with a target price of USUSD17.4, which represents an upside of 20.1% from the closing price of USUSD14.49 as at 27 January 2021. Jefferies reaffirms its positive stance on ICLK in light of BZUN deal and expect incremental revenue to kick-in in 2H21 with full year contribution in 2022. Jefferies expects the co-operation to leverage the expertise of both parties, which includes SaaS expertise of ICLK and operational capabilities of BZUN. The goal is to provide the most comprehensive solutions to brands which can benefit from the private domain t
vimarsana © 2020. All Rights Reserved.